Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artelo BiosciencesARTL -3.41%27 EV-to-OCF is 0.87 as of Aug. 11, 2026. GuruFocus rates ARTL with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, Artelo Biosciences ranks worse than 77.22% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Artelo Biosciences's Enterprise Value is $-7.10 Mil.
Artelo Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.11 Mil. Therefore, Artelo Biosciences's EV-to-OCF for today is 0.87.
The historical rank and industry rank for Artelo Biosciences's EV-to-OCF or its related term are showing as below:
ARTL'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.86 Med: 0 Max: 0.87
Current: 0.87
During the past 12 years, the highest EV-to-OCF of Artelo Biosciences was 0.87. The lowest was 0.86. And the median was .
ARTL's EV-to-OCF is ranked worse than 77.22% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs ARTL: 0.87
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Artelo Biosciences's PE Ratio (TTM) for today is calculated as:
Artelo Biosciences's share price for today is $0.71.
Artelo Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Artelo Biosciences EV-to-OCF Related Terms
Artelo Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Artelo Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Artelo Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's EV-to-OCF falls into.
Artelo Biosciences's current Enterprise Value is $-7.10 Mil.
Artelo Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artelo Biosciences (ARTL) has a EV-to-OCF of 0.87 as of Aug. 11, 2026. Over the past decade, Artelo Biosciences' EV-to-OCF has ranged from 0.86 to 0.87. According to the industry distribution chart, Artelo Biosciences ranks #1085 out of 1405 companies in the Biotechnology industry, placing it in the top 77.2%.
Is Artelo Biosciences' EV-to-OCF too high?
Artelo Biosciences' current EV-to-OCF is 0.87. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 0.87. Based on the distribution chart, Artelo Biosciences ranks #1085 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Artelo Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Artelo Biosciences' EV-to-OCF compare to ADTX and GOVX?
According to the Biotechnology industry distribution chart, Artelo Biosciences ranks #1085 out of 1405 companies for EV-to-OCF. This places Artelo Biosciences in the lower half of its industry. Historically, Artelo Biosciences' own EV-to-OCF has ranged from 0.86 to 0.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Artelo Biosciences's current EV-to-OCF is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artelo Biosciences stock overvalued right now?
Artelo Biosciences (ARTL) has a current EV-to-OCF of 0.87. The current EV-to-OCF is 0.87. Artelo Biosciences' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Artelo Biosciences (ARTL), the current EV-to-OCF is 0.87 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
27GF Score
Get the complete analysis for ARTL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTL has been successfully added to your 
